The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study.

ABSTRACT:

Introduction

The present study aims to evaluate the efficacy and safety of apatinib monotherapy or combination therapy for patients with advanced or recurrent biliary tract cancer (BTC).

Methods

Twenty-eight patients with advanced or recurrent BTC who progressed after prior systemic therapies and treated with apatinib from January 2017 to June 2019 were enrolled in this retrospective and observational study. The primary end point was progression free survival (PFS). Secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and toxicity.

Results

A total of 28 patients with advanced or recurrent BTC who progressed after prior systemic therapies received apatinib monotherapy or combination therapy (with capecitabine,

SUBMITTER: Nie C 

PROVIDER: S-EPMC7903638 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature